

Article

Single nanoparticle detection for multiplexed protein diagnostics with attomolar sensitivity in serum and unprocessed whole blood

Margo R Monroe, George G. Daaboul, Ahmet Tuysuzoglu, Carlos Lopez, Frédéric F. Little, and M. Selim Ünlü

Anal. Chem., **Just Accepted Manuscript** • DOI: 10.1021/ac4000514 • Publication Date (Web): 08 Mar 2013

Downloaded from <http://pubs.acs.org> on March 15, 2013

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications
High quality. High impact.

Analytical Chemistry is published by the American Chemical Society, 1155 Sixteenth Street N.W., Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Single nanoparticle detection for multiplexed protein diagnostics with attomolar sensitivity in serum and unprocessed whole blood

Margo R. Monroe¹, George G. Daaboul¹, Ahmet Tuysuzoglu², Carlos A. Lopez², Frédéric F. Little³, and M. Selim Ünlü^{*1,2,4}

¹Department of Biomedical Engineering, Boston University, 44 Cummington Street, Boston, Massachusetts, 02215; ²Department of Electrical and Computer Engineering, Boston University, 8 St. Mary's Street, Boston, Massachusetts, 02215; ³Pulmonary Center, Boston University School of Medicine, 715 Albany Street, Boston, Massachusetts 02118; ⁴Physics Department, Boston University, 590 Commonwealth Avenue, Boston, Massachusetts 02215.

*M. Selim Unlu: phone: 617-353-5067, email: selim@bu.edu

Abstract

Although biomarkers exist for a range of disease diagnostics, a single low-cost platform exhibiting the required sensitivity, a large dynamic-range and multiplexing capability, and zero sample preparation remains in high demand for a variety of clinical applications. The Interferometric Reflectance Imaging Sensor (IRIS) was utilized to digitally detect and size single gold nanoparticles to identify protein biomarkers in unprocessed serum and blood samples. IRIS is a simple, inexpensive, multiplexed, high-throughput, and label-free optical biosensor that was originally used to quantify biomass captured on a surface with moderate sensitivity. Here we demonstrate detection of β -lactoglobulin, a cow's milk whey protein spiked in serum (>10 orders of magnitude) and whole blood (>5 orders of magnitude), at attomolar sensitivity. The clinical utility of IRIS was demonstrated by detecting allergen-specific IgE from microliters of characterized human serum and unprocessed whole blood samples by using secondary antibodies against human IgE labeled with 40nm gold-nanoparticles. To our knowledge, this level of sensitivity over a large dynamic range has not been previously demonstrated.

IRIS offers four main advantages compared to existing technologies: it i) detects proteins from attomolar to nanomolar concentrations in unprocessed biological samples, ii) unambiguously discriminates nanoparticles tags on a robust and physically large sensor area, iii) detects protein targets with conjugated very small nanoparticle tags (~ 40 nm diameter), which minimally affect assay kinetics compared to conventional microparticle tagging methods, and iv) utilizes components that make the instrument inexpensive, robust, and portable. These features make IRIS an ideal candidate for clinical and diagnostic applications.

KEYWORDS: Single molecule, protein detection, attomolar sensitivity, point of care, whole blood diagnostics

Highly sensitive, quantitative, and multiplexed biomarker detection is a crucial focus for the technological development of next generation diagnostics.¹ Biomarkers are successful identifiers of diagnosis and prognosis in a variety of diseases from cancer to allergy. For example, nearly an 80% total decrease in cancer mortalities for colorectal, female breast, and prostate cancer have been largely due to improvements in early detection and treatment.² Likewise, determination of systemic sensitization to specific allergens has been established as the primary method to guide trigger avoidance.^{3, 4} Although protein biomarkers are known for a range of diseases, current multiplexed protein biosensors are subject to limitations: i) the absence of a large dynamic range assay to accurately detect all clinically relevant concentrations of a variety of biomarkers⁵ (See Table S1 for a partial list which expands over 5 orders of magnitude), ii) the inability to screen for a panel of biomarkers, versus a single biomarker, for reliable disease detection and monitoring^{6, 7}, iii) the challenge of maintaining sensitivity and specificity in unprocessed whole blood or minimally prepared serum samples⁸, and iv) the need for the biosensor platform to be robust, portable, and versatile⁹.

Biomarkers in serum have been detected using a variety of transduction and amplification mechanisms, such as electrochemical^{10, 11}, mechanical^{12, 13}, or optical^{14, 15} techniques; micro/nanoparticle tagging and single molecule detection methods are often used to achieve very high sensitivity. One particular sensing approach termed the bio-barcode assay developed by Stoeva *et al.* uses AuNPs as secondary probes to detect protein targets. Once bound, the tags are additionally stained with silver to amplify the signal to achieve high sensitivity from the attomolar to picomolar range in a multiplexed format.^{15, 16} Furthermore, single molecule quantification has been demonstrated by detecting binary events to achieve digital sensing.^{17, 18} For example, Rissin *et al.* have developed a single-molecule ELISA method to detect proteins at

1
2
3 subfemtomolar concentrations over 4 orders of magnitude in serum.¹⁸ These techniques require
4
5 that the biomarkers of interest be within the dynamic range of the platform and that whole blood
6
7 samples must be processed prior to testing. Moreover, nanoscale and complex sensing elements
8
9 used in these single particle detection techniques may limit clinical applicability such as point of
10
11 care testing.^{19, 20}
12
13

14
15 Protein detection at attomolar sensitivity in serum has also been achieved by using
16
17 microparticles with diameters between 1-200 μ m attached to secondary antibodies.²¹ While the
18
19 large size of these microparticles allows for visibility in a conventionally acquired image, they
20
21 are known to severely reduce the diffusivity ($\sim$ 3-4 orders of magnitude (Fig. S1)) and thus
22
23 require external force fields.²² Moreover, once the microparticle tag exceeds 3 μ m in diameter,
24
25 the particle will settle out of solution and only undergo 2D diffusion and may cause the assay
26
27 outcome to be inaccurate.^{21, 22} To maintain native kinetics of the particle-probe complex, it is
28
29 crucial that the particle tag be on a similar size scale as the target.
30
31
32
33

34 While highly sensitive protein detection methods have been achieved in serum samples,
35
36 biomarker detection in unprocessed whole blood remains very challenging due to non-specific
37
38 binding of cells and particulates to the sensor surface. One approach to perform biosensing in
39
40 whole blood samples has been demonstrated by Stern *et al.*, who have developed a
41
42 microfabricated microfluidic purification chip to process 10 μ L of whole blood in 20 minutes.²³
43
44 However, this technique only achieves 500pM sensitivity, which is 10^6 times less sensitive than
45
46 the techniques established for detection in serum. Moreover, this level of sensitivity is not
47
48 pertinent to most protein biomarkers, whose serum concentrations in healthy individuals range
49
50 between 0.01-100pM (Table S1).
51
52
53
54
55
56
57
58
59
60

Here, we demonstrate the ability of IRIS to perform discrete detection of allergen-specific IgE, a biomarker of allergy, in unprocessed whole blood samples with negligible non-specific binding from the attomolar to picomolar range by discriminating 40nm AuNP tags, with negligible effect on binding kinetics, functionalized to secondary antibodies over a physically large and robust sensor surface. The IRIS technique has been first demonstrated for label-free, and quantitative measurements of biomass captured on the sensor surface^{24, 25} and recently modified to detect single nanoparticles across a large sensor surface using only basic optical components: a simple, inexpensive, silicon-silicon oxide (Si-SiO₂) substrate; commercially available LEDs; and a CCD detector.²⁶ Typical optical sensors designed to detect single nanoparticles utilize micro-fabricated devices with small surface areas.^{27, 28} IRIS uses a simple planar surface that is easy to multiplex and does not require micro-fabricated features. Instead, IRIS benefits from enhanced visibility due to interference of optical field scattered from captured nanoparticles interfering with the reference reflection from the layered surface. In this imaging sensor modality, each diffraction-limited spot creates the opportunity to detect a single binding event on the IRIS substrate effectively yielding as many as 10⁶ parallel sensing elements with discrete detection capability.²⁹

The primary differences in the total biomass quantification and single nanoparticle counting modalities of IRIS are the magnification of the objective, the oxide spacer on the substrate, and the resulting information of the image acquired by the CCD array (Fig. S2). The first modality (low magnification) of IRIS quantifies biomass on a surface by converting the intensity value of each pixel in the CCD array into an average optical height measurement. The second modality (high magnification) of IRIS detects, size discriminates and counts individual AuNP. The resulting discrete detection of nanoparticle tags provides the ability to distinguish the specific binding events in complex solutions allowing for detection in serum and whole blood with high

1
2
3 sensitivity. However, discrete detection requires that the density of nanoparticles on the surface
4
5 is no more than one per diffraction limited spot and thus has an upper limit in detection
6
7 concentration. In practice, for unambiguous discrimination of individual AuNP tags from the
8
9 background a relatively low density on the surface, less than 10^4 particles/mm² is desirable
10
11 imposing a limit on the dynamic range. While the discrete detection saturates at the high target
12
13 protein concentration, the sensitivity of the low-magnification modality of IRIS would become
14
15 sufficient and thus provide label-free total biomass quantification. These complementary
16
17 modalities may be achieved in a single instrument by changing the optical magnification, similar
18
19 to different objectives on a microscope turret, and result in high sensing capability.
20
21
22
23

24 We utilize IRIS technology to detect allergen-specific IgE in finger-prick volumes of
25
26 characterized patient serum and whole blood samples. Allergy is a disorder of the immune
27
28 system caused by an immune response to otherwise harmless environmental allergens. Currently
29
30 20% of the US population is allergic and 90% of pediatric patients and 60% of adult patients
31
32 with asthma have allergies. These percentages are predicted to increase by 18.5% in the next
33
34 decade.³⁰⁻³² While a variety of commercialized assays (ImmunoCAP®, Siemens, Hycor
35
36 Biomedical, Hitachi Chemical Diagnostics, Luminex Corporation) have been developed for
37
38 allergy diagnostics in the laboratory setting, the ImmunoCAP® Rapid System (Thermo-Fisher
39
40 Scientific) is the only commercialized allergen-specific IgE test that can operate with
41
42 unprocessed blood samples. This assay uses a capillary blood draw of 100 microliters and totals
43
44 25 minutes of testing while other commercialized assays take 1 hour of sample preparation in
45
46 addition to over 4 hours of assay time.^{33, 34} However, the Rapid System is limited to
47
48 aeroallergens, has a narrow dynamic range, and requires professional interpretation of results
49
50 because it is not quantitative. IRIS is a combined label and label-free platform that offers the
51
52
53
54
55
56
57
58
59
60

ability to detect biomarkers in small volumes of unprocessed whole blood over 5 orders of magnitude and in serum over 10 orders of magnitude with high accuracy and reproducibility.

Results and Discussion

This report focuses on the single nanoparticle counting modality of the IRIS platform. The novel, yet straightforward, features of this modality have facilitated the design of a highly sensitive (attomolar), large dynamic range (attomolar to nanomolar), quantifiable, and multiplexed immunoassay in both serum and whole blood using 40nm AuNPs functionalized secondary antibodies (Fig. 1). The unique ability to detect single nanoparticles over a large sensor area with the IRIS platform allows the use of nanoparticle tags that are in the size regime of the target molecules without sacrificing the kinetics of the reaction (Fig. S1). Moreover, the platform maintains the ability to detect target at attomolar quantities in unprocessed whole blood. Discrimination of nanoparticle tags^{29, 35} and a large sensor size contribute to the low limit of detection (LOD) of the assay. Finally, large multiplexing capability and clinical applicability of the IRIS platform is demonstrated by testing characterized serum and whole blood samples with documented allergen-specific IgE levels. The results were compared to ImmunoCAP® characterization for platform validation (Fig. 4).

Quantification and verification of bound AuNPs using elimination processes on IRIS

IRIS nanoparticle images were acquired and processed with custom software. IRIS software returns a histogram of the size distribution of nanoparticles in the image and uses 3 important elimination processes – anomaly filtering, point-spread-function (PSF) filtering, and size-discrimination – to ensure accurate and sensitive detection of labeled detection antibodies (Figs. 1c, 2). Figs. 1c and 2 demonstrate the importance of eliminating particles in the image that are not the functionalized AuNPs used specifically for target detection. Without filtering, the average

size and standard deviation of the particles detected on the surface was $59 \pm 18 \text{ nm}$ corresponding to larger size than expected for the AuNP tags indicated that many of the “detected” particles are image artifacts also indicated by the very large size distribution. After using IRIS elimination processes, the average size and standard deviation of detected nanoparticles was reduced to $53 \pm 4 \text{ nm}$, which was the diameter of the functionalized AuNPs confirmed with dynamic light scattering (DLS). Likewise, the dynamic range of the assay was improved by 4 orders of magnitude after applying the elimination processes (Fig. 2). Because aberrations in the image may affect the calculated particle size, AuNPs $54 \pm 10 \text{ nm}$ in diameter were analyzed to quantify the number of binding events during dilution experiments.

Attomolar detection of β -lactoglobulin in undiluted serum and unprocessed whole blood

IRIS single particle counting digitally detected β -lactoglobulin spiked in 1 mL of undiluted serum or unprocessed whole blood and improved upon the dynamic range and sensitivity of the IRIS biomass platform (Fig. 3). Analysis of the nanoparticle counting data resulted in a 10^7 -fold increase in repeatable sensitivity from the nanomolar to the attomolar regime in unprocessed biological samples (Fig. 3a). Post AuNP incubation images of immobilized anti- β -lactoglobulin and BSA probes incubated with β -lactoglobulin at various dilutions are presented in Fig. S3. Protein microarrays are notorious for inconsistent or poor morphologies and a detection platform must not be compromised because of these intrinsic, and often unavoidable features^{36, 37}. Furthermore, serum and whole blood contain non-homogenous particulates and cells that may affect detection sensitivity and range. Thus, the ability to discriminate against any false signal and/or non-specific binding caused by these features is crucial for reducing noise of the assay. The ability to automatically discriminate AuNPs from non-specific particles provides IRIS with a method to reduce the biological noise associated with the use of complex samples. Overall, this

feature of the nanoparticle counting modality is key to producing reliable, sensitive detection of target in serum and unprocessed whole blood. Fig. S3 includes examples of poor immobilization of anti- β -lactoglobulin and BSA probes. It is crucial that the non-homogeneity of the spot does not affect nanoparticle quantification. By instituting the IRIS elimination processes, only AuNPs introduced by the user are detected in the image. Likewise, the biomass measurement was previously shown to correct variation in allergy chips and is reported elsewhere.³⁸

A schematic of the assay and the signal minus the LOD of each modality are shown in Fig. 3a. Repeatability of the assay is shown in Fig. 3b. Anti- β -lactoglobulin probes were used to capture target from the complex solution. BSA probes were used as a negative control. The LOD of the nanoparticle counting modality was calculated to be ~ 60 aM in undiluted serum and ~ 500 aM in unprocessed whole blood (See *Supportive information* for details on defining the limit of detection). Using fluorescently labeled secondary antibodies, the LOD of the same protein system was found to be 163 fM in PBS.³⁹ As the response of nanoparticle counting saturates, the biomass (low magnification) measurement in serum becomes sufficiently sensitive at 2 nM and linearly increases. Unfortunately, the biomass measurement fails in whole blood due to large amounts of non-specific binding to the sensor surface, and this causes the dynamic range of the IRIS platform to be reduced from 10 orders of magnitude in serum to about 5 orders of magnitude in whole blood.

Although attomolar sensitivity has been matched by other methods^{40, 41}, these techniques currently have not reported the ability to perform highly sensitive detection of biomarkers over a large dynamic range in unprocessed, complex biological samples. Furthermore, these techniques require microparticle tags, multiple amplification steps, nanoscale elements, and/or expensive instrumentation that may not be suitable for clinical applications, such as POC testing. With

improved sensitivity and dynamic range, IRIS can be implemented as a single, simple instrument to quantify a wide range of biomarkers of varying concentrations in undiluted serum and unprocessed whole blood in a single test.

Advantages of increasing biological sensor area to improve assay sensitivity

Multiplexing capacity is a desirable criterion for biosensors developed for clinical applications. High-throughput platforms generally perform multiple tests in a minimum of 3 replicates to calculate a mean and standard deviation of each test. These tests run a ‘blank’ sample in parallel to compute the LOD (mean plus 3 times the standard deviation) of the assay. The number of wells or the sensor area usually limits the total number of tests a platform may perform. Thus, a compromise between the number of tests and the number of replicates of each test must be determined in order to collect meaningful data that will contribute to the detection of multiple biomarkers with potentially different sensitivity thresholds; for example, an increase in multiplexing capability results in a decreased ability to replicate each test because the available sensor area is dedicated to multiplexing. The effect of sensor size per test is studied as a function of sensor area to highlight these considerations (Fig. 4).

The occurrence of independent and random binding events becomes discrete when sufficiently low numbers of target molecules are in solution and may be maximized by increasing the sensor area.⁴² Similarly, a larger sensor area reduces the variance of stochastic noise of the system such as non-specific binding. Here, the surface area of immobilized probes on the IRIS substrate describes the sensor area, n . The LOD per mm^2 as a function of sensor size for serum and whole blood samples on the IRIS platform is shown in Fig. 4. The LOD per mm^2 is defined as the average signal (AuNPs/mm^2) of a defined sensor size plus 3 times the standard deviation from the mean. Standard deviation is a function of sample size, n , which scales by $\frac{1}{\sqrt{n}}$. As expected,

an increase in sensor size causes the LOD per mm^2 to decrease by $\frac{1}{n}$ and level off at a constant value representative of the mean ($R^2 = 1.0$) for both serum and whole blood measurements (See Fig. S4 for details on calculation of LOD and regression). At a sensor area of 0.684 mm^2 (approximately 8 spots of immobilized anti- β -lactoglobulin probes), the LOD per mm^2 is 62aM in serum and 507aM in whole blood. Conventional tests utilize 3 replicates to calculate the LOD of their platform. Based on our measurements, if we utilized a sensor area of a single spot (area $\sim 0.0855 \text{ mm}^2$), the LOD per mm^2 is 322aM in serum and 46fM in unprocessed whole blood. Theoretically, if sensor area were infinite in size, the LOD per mm^2 for both serum and whole blood would approach 10aM. Although an order of magnitude of sensitivity is lost in whole blood samples when a sensor area of 0.684 mm^2 (~ 8 spots) is used, this level of sensitivity in unprocessed whole blood samples is, to our knowledge, unmatched by other technologies that sense single molecular targets in unprocessed whole blood. Because a single nanoparticle can be detected on the IRIS substrate, the primary limitation of the platform becomes the ability to increase the capture efficiency of molecules in solution.

Determination of the lower limit of quantitation (LLQ) and upper limit of quantitation (ULQ)

The LLQ per mm^2 for the β -lactoglobulin assay was 260aM in serum and 15fM in unprocessed whole blood using a sensor area of 0.684 mm^2 . Commercialized allergen-specific IgE assays, such as ImmunoCAP® (Phadia), Immulite (Siemens), and Turbo RAST (Hycor Biomedical), that detect allergen-specific IgE are typically carried out in ELISA format. Luminex Corporation recently commercialized an allergy assay with xMAP Technology (Luminex Corp). An analytical comparison of the two assays demonstrated the LLQ of ELISA to be $\sim 600 \text{ fM}$ and the LLQ of xMAP MAGPIX Technology to be $\sim 100 \text{ fM}$ when running a $\text{TNF}\alpha$ MAGPIX assay.^{33, 34} These commercialized assays are limited to only serum samples and small sensor areas. IRIS

technology is 1000 times more sensitive in serum and 10 times more sensitive in unprocessed whole blood samples. The ULQ for the β -lactoglobulin assay in serum was determined to be 100pM in serum and whole blood samples using IRIS single nanoparticle counting (Fig. 5). ELISA and xMAP MAGPIX assays each have a ULQ of $\sim$ 100pM, respectively.^{33, 34}

Quantification of allergen-specific IgE in characterized serum and whole blood using IRIS nanoparticle counting

The multiplexing capability and clinical applicability of IRIS nanoparticle counting was determined by detecting allergen-specific IgE in 50 μ L characterized patient serum and unprocessed whole blood against a panel of 8 purified major allergens immobilized in quadruplets. Fluorescence detection of specific IgE in serum was used as a control to validate IRIS nanoparticle detection of specific IgE in serum and whole blood. The average and standard deviation (N=4) of fluorescence and nanoparticle counting measurements were confirmed with Phadia ImmunoCAP® (Fig. 6). The nanoparticle counting measurements were correlated to the fluorescence results to validate the assay ($R_{\text{serum}}^2 = 0.97$, $R_{\text{whole-blood}}^2 = 0.97$). The standard deviations of the fluorescence measurements were larger than the standard deviations of the nanoparticle counting measurements in serum and unprocessed whole blood. This is a direct result of the ability to detect discrete binding events on immobilized probes; spot-to-spot morphology inconsistencies, which are notoriously present in protein microarrays, were averaged in the fluorescence measurement and contributed to larger deviation. Although the fluorescence and nanoparticle counting measurements detected minimal IgE bound to Bet v 1 (birch), the ImmunoCAP® reports slight elevated levels of specific IgE (specific IgE – Fluorescence: 16 $\pm$ 11 SNR, Nanoparticle counting: 4 $\pm$ 7 AuNPs/mm², ImmunoCAP®: 0.69 kU/L). This low signal is most likely due to low immobilization of Bet v 1 probes that has been quantified by the IRIS

1
2
3 biomass measurement on the sensor surface.³⁸ Furthermore, measurement of IgE to Ara h 2
4 (peanut) and Bet v 1 on the whole blood chip was not reported due to spotting inconsistencies
5 (Fig. S5). The ability to quantify immobilization density of each spot in the array highlights the
6 need of an instrument to be capable of quantitative assessment to guarantee reliable, accurate test
7 results and has been demonstrated elsewhere.³⁸ This is one example of the two modalities of
8 IRIS complement each other. Overall, IRIS data corresponds well to the ImmunoCAP®. This is
9 one example where the two modalities of IRIS can complement each other to improve general
10 assay performance. These results demonstrate the ability of IRIS to perform multiplexed testing
11 at attomolar sensitivity in unprocessed, finger-prick volumes of whole blood.
12
13
14
15
16
17
18
19
20
21
22
23

24 **Conclusions**

25
26 We have demonstrated highly sensitive, multiplexed biomarker detection over a large dynamic
27 range in unprocessed biological samples with IRIS, a simple instrument with potentially broad
28 clinical impact, by implementing the advantages of nanoparticle tagging, single nanoparticle
29 discrimination, and a large surface area, robust sensor. As proof of concept, β -lactoglobulin, a
30 cow's milk whey protein, was detected against negative controls at a detection limit of ~60aM in
31 serum and ~500aM in whole blood. The upper limit was calculated to be ~100pM. This
32 sensitivity and dynamic range in biological media with no sample preparation are direct results
33 of the ability of IRIS to i) eliminate all nanoparticles not specific to the assay and ii) detect single
34 nanoparticles over a large sensor surface. Furthermore, multiplexing capability and clinical
35 applicability were demonstrated by using finger-prick volumes of characterized patient serum
36 and whole blood samples. Currently IRIS requires no time for sample preparation and 3 hours for
37 assay time, which may potentially be reduced with the incorporation of microfluidics.⁴³ The
38 elimination of sample preparation would reduce total assay time by 1 hour and permit the test to
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

be performed outside of laboratory environments and therefore improve the utility of the system. The use of LEDs, simple optics, and inexpensive substrates to quantify multiple targets in complex samples establish IRIS as a promising platform for diverse clinical purposes.

Materials and Methods

Reagents and equipment

Bovine serum albumin (BSA), β -lactoglobulin, Tween 20, high purity poly(ethylene glycol-8K) (PEG), Ethylenediaminetetraacetic acid (EDTA), and PBS tablets were purchased from Sigma (St. Louis, MO). Rabbit anti- β -lactoglobulin was purchased from Bethyl Laboratories (Montgomery, TX). 40nm carboxylated gold nanoparticles (AuNPs) were purchased from Cytodiagnostics (Ontario, Canada). MES buffered saline packs, EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Hydrochloride), and Sulfo-NHS (N-hydroxysulfosuccinimide) were purchased from Thermo Fisher Scientific (Rockford, Illinois). Copoly(DMA-NAS-MAPS)⁴⁴ was purchased from Lucidant polymers. The Bio-Rad Calligrapher (Bio-Rad Laboratories, Inc.) was used for protein printing on chips. Anti-IgE was purchased from BDBiosciences. Allergens Der p 1, Phl p 1, Ara h 1, Ara h 2, Bet v 1, Mal d 1, and Phl p 1 were purchased from Indoor Biotechnologies Ltd (Warminster, UK). Cy3 labeling kit was purchased from GE Healthcare.

Si-SiO₂ chip fabrication

Silicon chip fabrication is described elsewhere³⁹. Briefly, chips consisting of region of a bare silicon reference region, an oxide of 500nm, and an oxide of 100nm were used for optimized IRIS biomass measurement (500nm) and single particle counting (100nm). Each oxide spacer was engineered and optimized to a specific thickness in order to maximize the contrast for both biomass measurement (500nm) and nanoparticle counting (100nm) on Si-SiO₂ substrate^{24, 29}.

Surface functionalization

The surface of the silicon chip was functionalized with copoly(DMA-NAS-MAPS)⁴⁴ due to the feasibility and reproducibility of its synthesis, coating process, and antifouling properties. This particular polymeric coating does not affect the optical properties of the system. Si-SiO₂ slides were immersed for 30 minutes in a solution of the polymer at 1% w/v concentration in a solution of deionized water and 20% saturated ammonium sulphate. Slides were washed with water for 5 minutes and dried in vacuum at 80°C for 15 minutes.

Optical detection

Two modalities of IRIS were employed in this work. The differences between the two IRIS modalities (total biomass measurement vs. single nanoparticle counting) are i) the magnification of the optical imaging system, ii) the oxide spacer (500nm vs. 100nm) on the Si substrate, and iii) the forward models used to interpret the response detected by the CCD camera. The first modality measures biomass accumulation in microarray format on the surface and is described thoroughly elsewhere²⁴. Briefly, four discrete LEDs sequentially illuminate the sensor surface through a low magnification objective. The light reflected from the Si-SiO₂ substrate creates an interference signature, and the intensity images are recorded onto a CCD camera. The data from each of the pixels of the camera are processed with custom software to quantify the optical thickness between the two reflecting surfaces and then converted into a height image over the entire field of view. As biomass accumulates on the sensor's surface, the optical thickness increases and is quantified. The second modality of IRIS uses one discrete LED wavelength (525nm) to illuminate the sensor's surface using a high magnification objective (50X, 0.8NA) to detect, count, and size nanoparticles of known material located on the SiO₂ surface and is thoroughly described elsewhere^{26, 29}. Briefly, this modality of IRIS enhances the contrast of a

single nanoparticle on a bilayered substrate by interfering the scattered field produced by the nanoparticle on the substrate surface with the reflected field generated by the buried Si-SiO₂ interface of the IRIS chip. The CCD camera senses the individual nanoparticles on the IRIS chip as point objects, which are processed via custom software to extract size information.

The optical setups of each modality of IRIS are detailed in the supplementary material (Fig. S2).

AuNP functionalization of secondary detection antibody, anti- β -lactoglobulin

To functionalize the AuNPs to the detection antibody, the purchased carboxylated 40nm AuNPs were diluted to a solution containing $\sim 10^{10}$ particles/mL. The particles were then incubated in 2:1 EDC/NHS in 0.1 MES buffer (pH 6) for 30 minutes. The particles were then spun down, the supernatant was removed, and the particles were exposed overnight to the detection antibody at 10 μ g/mL in PBS buffer. The functionalized particles were then washed with 1%BSA w/v in PBS, 0.02% Tween in PBS, and stored in 0.1% BSAw/v, 0.1%w/v PEG in PBS.

Verification of AuNP size after functionalization of secondary detection antibody

The diameters of the carboxylated AuNPs pre- and post- anti- β -lactoglobulin functionalization were verified with Dynamic Light Scattering (DLS) technology manufactured by Malvern Instruments Ltd. DLS reported the carboxylated AuNPs to be 51nm in diameter prior to antibody functionalization and 54nm after antibody functionalization. To discriminate AuNPs against particulates in the IRIS images, only AuNPs 53 $\pm$ 10nm were quantified as labeled secondary antibody to its target.

Protein immobilization on chip

Dilution in serum and whole blood protein immobilization: Twenty IRIS chips were functionalized with the polymeric coating. Ten chips were printed with 8 replicates of anti- β -lactoglobulin (positive control) and BSA (negative control) at 1mg/mL and stored overnight at room temperature in a humid environment and used for testing undiluted serum. The remaining 10 chips were printed with 4 replicates of anti- β -lactoglobulin (positive control) and BSA (negative control) at 1mg/mL and stored overnight at room temperature in a humid environment and used for testing whole blood. The chips were then washed 3 times each for 5 minutes in PBST and PBS buffers, rinsed with DI water, and dried with a stream of argon gas. Probe immobilization was then quantified with the IRIS biomass measurement.

Multiplexed allergen immobilization: Three chips were functionalized with the polymeric coating. The chips were printed with 4 replicates of 8 allergens – Der p 1, Phl p 1, Ara h 1, Ara h 2, Bet v 1, Mal d 1, and Phl p 1 – at 1mg/mL and stored overnight at room temperature in a humid environment. The chips were then washed 3 times each for 5 minutes in PBST and PBS buffers, rinsed with DI water, and dried with a stream of argon gas. Probe immobilization was then quantified with the IRIS biomass measurement.

Assay to detect β -lactoglobulin targets spiked in undiluted serum or unprocessed whole blood

After quantification of probe immobilization density, each chip was incubated in 1mL volume of undiluted serum or unprocessed whole blood spiked with β -lactoglobulin target antigen at 5.4fM (0.1pg/mL), 54fM (1pg/mL), 540fM (10pg/mL), 5.4pM (100pg/mL), 54pM (1ng/mL), 5.4nM (100ng/mL), and 54nM (1 μ g/mL) for 2 hours. Three chips were incubated in pure undiluted serum as blanks to quantify any unspecific particle binding as background noise or false detection. Chips were then washed with PBST buffer for 10 minutes (5mM of EDTA was added for whole blood samples), rinsed in water, and dried with a stream of argon gas. IRIS

1
2
3 biomass measurements were then taken to observe any changes in mass accumulation on chip.
4
5 The chips were then incubated in $\sim 10^8$ functionalized AuNPs/mL in 5%w/v BSA/PBS for 1
6
7 hour, washed in PBS for 10 minutes, rinsed in water, and dried with a stream of argon gas. The
8
9 chips were finally scanned with the IRIS single particle modality to quantify bound AuNPs.
10
11

12 *Assay to detect allergen-specific IgE in characterized patient serum and whole blood*

13
14 Specific IgE to relevant allergens was quantified by ImmunoCAP (Phadia) on patient serum.
15
16 After quantification of probe immobilization density, 2 chips were incubated in 50 μ L volume of
17
18 serum and 1 chip was incubated with whole blood anticoagulated with EDTA for 2 hours. Chips
19
20 were then washed with PBST buffer for 10 minutes (5mM of EDTA was added for whole blood
21
22 samples), rinsed in water, and dried with a stream of argon gas. One chip incubated with serum
23
24 and the chip incubated in whole blood were then incubated in $\sim 10^8$ anti-IgE-functionalized
25
26 AuNPs/mL in 5%w/v BSA/PBS for 1 hour. The third chip was incubated in Cy3-anti-IgE
27
28 (1ng/mL) for 1 hour. The 3 chips were then washed in PBS for 10 minutes, rinsed in water, and
29
30 dried with a stream of argon gas. The chips were finally scanned with the IRIS single particle
31
32 modality to quantify bound AuNPs.
33
34
35
36
37

38 *Elimination processes to ensure accurate detection of AuNPs with IRIS*

39
40 IRIS nanoparticle counting software incorporates 3 elimination processes to ensure that point
41
42 objects detected in the image are AuNP-functionalized secondary antibodies. First, anomaly
43
44 filtering disregards any irregular points caused by the morphology of the protein spot. Second, a
45
46 point spread function (PSF) filter disregards any particles on the surface that do not exhibit the
47
48 expected profile of the AuNPs; the profile of a AuNP takes form of the point spread function of
49
50 the optical system that is known in advance. PSF filtering is crucial: spot morphologies often
51
52 contain particulates that may be misconstrued as false positives; thus, it is important to utilize the
53
54
55
56
57
58
59
60

expected PSF profile to ensure accurate AuNP detection. Third, the size-discrimination feature of IRIS nanoparticle counting eliminates any particulates outside of the size regime of the introduced AuNPs.

Determination of the limit of detection (LOD)

The LOD of the IRIS platform, in accordance with all measurements acquired with the single nanoparticle counting modality, is defined as the LOD per mm^2 in serum and whole blood. Three chips incubated in blank serum or blank whole blood were grouped as a single experiment to yield 24 tests for serum (8 spots per chip) or 12 tests for whole blood (4 spots per chip). The background signal (AuNPs per spot) of the tests on the blank chips follows a normal distribution (Fig. S6); therefore, we can combine the 3 chips as a single experiment. We measured each test, or spot consisting of immobilized probes, to be a sensor area consisting of 0.0855mm^2 . The numbers of detected AuNPs on each test were taken in combinations from 1 (0.0855mm^2) to 9 (0.7695mm^2) spots to study the effect of increasing effective sensor size on the LOD per mm^2 . Because the whole blood chips consisted of less spots, combinations from 1 to 6 spots were taken. The average of the AuNPs per mm^2 plus 3 times the standard deviation was determined as the background signal (AuNPs per mm^2) for the defined sensor area. Note, the average always stays constant; however, the standard deviation changes with the sensor size, n , by a factor of $n^{-0.5}$. Thus, the data was fitted with $y = A \cdot n^{-0.5} + B$ using linear regression and 95% confidence bounds to determine the dependence of the background signal on the sensor area (Fig. S4a). The background signal was then used to extrapolate a target concentration using the linear regression described by the log-log plot of AuNPs per mm^2 versus target concentration (Fig. S4b).

Determination of the lower and upper limits of quantitation

1
2
3 A number of different “detection limits” may be used to characterize the minimum and
4
5 highest concentration reliably measured by an analytical procedure. Typically, the LOD is
6
7 calculated to report the minimum concentration of the analyte that can be detected with less than
8
9 1% false positive error. The lower limit of quantification (LLQ) and the upper limit of
10
11 quantification (ULQ) are calculated when a higher degrees of confidence is desired, such as in
12
13 commercialized clinical assays. The LLQ was calculated as described in the *Determination of the*
14
15 *Limit of Detection* methods section; however, while the LOD was calculated using 3 times the
16
17 standard deviation from the mean, the LLQ was calculated using 10 times the standard deviation
18
19 from the mean.
20
21
22
23
24

25 The ULQ was defined as the target concentration at which linear regression of the dilution
26
27 curve became less than $R^2 = 0.90$ for i) serum and ii) unprocessed whole blood samples. Target
28
29 concentrations from 5.4fM to 5nM were fit over 4, 5, and 7 orders of magnitude (Fig. 5) for
30
31 serum and unprocessed whole blood samples to determine when the linear correlation between
32
33 the signal and target concentration fell below $R^2 = 0.90$.
34
35
36
37

38 ACKNOWLEDGEMENT

39
40

41 Financial support from the Wallace H. Coulter Foundation 2010 Coulter Translational Award,
42
43 by the SmartLighting ERC funded via the NSF under Cooperative Agreement EEC-0812056,
44
45 and by the National Institute of Health under R21EB015900. Acknowledgement also goes to the
46
47 Center for integration of Medicine and Innovative Technology (CIMIT) and Ahmet Tuysuzoglu
48
49 for the development of the IRIS single particle detection software.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SUPPORTING INFORMATION

The manuscript details the materials and methods presented in the SI and refers to the results as seen in Fig. S1.

This material is available free of charge via the Internet at <http://pubs.acs.org>

REFERENCES:

- (1) Gubala, V.; Harris, L.; Ricco, A.; Tan, M.; Williams, D., Point of Care Diagnostics: Status and Future. *Analytical Chemistry* **2012**, 84, 487-515.
- (2) Jemal, A.; Clegg, L. X.; Ward, E.; Ries, L. A. G.; Wu, X.; Jamison, P. M.; Wingo, P. A.; Howe, H. L.; Anderson, R. N.; Edwards, B. K., Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. **2004**, 101, 27.
- (3) Gruchalla, R. S.; Pongracic, J.; Plaut, M.; Evans, R.; Visness, C. M.; Walter, M.; Crain, E. F.; Kattan, M.; Morgan, W. J.; Steinbach, S.; Stout, J.; Malindzak, G.; Smartt, E.; Mitchell, H., Inner City Asthma Study: Relationships among sensitivity, allergen exposure, and asthma morbidity. *J Allergy Clin Immun* **2005**, 115, 478-485.
- (4) Morgan, W. J.; Crain, E. F.; Gruchalla, R. S.; O'Connor, G. T.; Kattan, M.; Evans, R. I.; Stout, J.; Malindzak, G.; Smartt, E.; Plaut, M.; Walter, M.; Vaughn, B.; Mitchell, H.; Grp, I. C. A. S., Results of a home-based environmental intervention among urban children with asthma. *New Engl J Med* **2004**, 351, 1068-1080.
- (5) Rusling, J.; Kumar, C.; Gutkind, J.; Patel, V., Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. *Analyst* **2010**, 135, 2496-2511.
- (6) Ebert, M.; Korc, M.; Malfertheiner, P.; Rocken, C., Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. *Journal of Proteome Research* **2006**, 5, 19-25.
- (7) Tothill, I., Biosensors for cancer markers diagnosis. *Seminars in Cell & Developmental Biology* **2009**, 20, 55-62.
- (8) Yager, P.; Domingo, G.; Gerdes, J., Point-of-care diagnostics for global health. *Annual Review of Biomedical Engineering* **2008**, 10, 107-144.
- (9) Giljohann, D.; Mirkin, C., Drivers of biodiagnostic development. *Nature* **2009**, 462, 461-464.

- (10) Li, R.; Wu, D.; Li, H.; Xu, C.; Wang, H.; Zhao, Y.; Cai, Y.; Wei, Q.; Du, B., Label-free amperometric immunosensor for the detection of human serum chorionic gonadotropin based on nanoporous gold and graphene. *Analytical Biochemistry* **2011**, 414, 196-201.
- (11) Wu, S.; Lan, X.; Huang, F.; Luo, Z.; Ju, H.; Meng, C.; Duan, C., Selective electrochemical detection of cysteine in complex serum by graphene nanoribbon. *Biosensors & Bioelectronics* **2012**, 32, 293-296.
- (12) Lee, J.; Choi, Y.; Lee, Y.; Lee, H.; Lee, J.; Kim, S.; Han, K.; Cho, E.; Park, J.; Lee, S., Sensitive and Simultaneous Detection of Cardiac Markers in Human Serum Using Surface Acoustic Wave Immunosensor. *Analytical Chemistry* **2011**, 83, 8629-8635.
- (13) Craighead, H., Nanoelectromechanical systems. *Science* **2000**, 290, 1532-1535.
- (14) Chen, J.; Wang, C.; Irudayaraj, J., Ultrasensitive protein detection in blood serum using gold nanoparticle probes by single molecule spectroscopy. *Journal of Biomedical Optics* **2009**, 14.
- (15) Stoeva, S.; Lee, J.; Smith, J.; Rosen, S.; Mirkin, C., Multiplexed detection of protein cancer markers with biobarcode nanoparticle probes. *Journal of the American Chemical Society* **2006**, 128, 8378-8379.
- (16) Cheng, M.; Cuda, G.; Bunimovich, Y.; Gaspari, M.; Heath, J.; Hill, H.; Mirkin, C.; Nijdam, A.; Terracciano, R.; Thundat, T.; Ferrari, M., Nanotechnologies for biomolecular detection and medical diagnostics. *Current Opinion in Chemical Biology* **2006**, 10, 11-19.
- (17) Jarvius, J.; Melin, J.; Goransson, J.; Stenberg, J.; Fredriksson, S.; Gonzalez-Rey, C.; Bertilsson, S.; Nilsson, M., Digital quantification using amplified single-molecule detection. *Nature Methods* **2006**, 3, 725-727.

- (18) Rissin, D.; Kan, C.; Campbell, T.; Howes, S.; Fournier, D.; Song, L.; Piech, T.; Patel, P.; Chang, L.; Rivnak, A.; Ferrell, E.; Randall, J.; Provuncher, G.; Walt, D.; Duffy, D., Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. *Nature Biotechnology* **2010**, 28, 595-U25.
- (19) Resch-Genger, U.; Grabolle, M.; Cavaliere-Jaricot, S.; Nitschke, R.; Nann, T., Quantum dots versus organic dyes as fluorescent labels. *Nature Methods* **2008**, 5, 763-775.
- (20) Wadkins, R. M.; Ligler, F. S., Immunobiosensors Based on Evanescent Wave Excitation. **1998**; 7, 77-87.
- (21) Mulvaney, S., BIOSENSORS Magnets tackle kinetic questions. *Nature Nanotechnology* **2011**, 6, 266-267.
- (22) Mulvaney, S.; Myers, K.; Sheehan, P.; Whitman, L., Attomolar protein detection in complex sample matrices with semi-homogeneous fluidic force discrimination assays. *Biosensors & Bioelectronics* **2009**, 24, 1109-1115.
- (23) Stern, E.; Vacic, A.; Rajan, N.; Criscione, J.; Park, J.; Ilic, B.; Mooney, D.; Reed, M.; Fahmy, T., Label-free biomarker detection from whole blood. *Nature Nanotechnology* **2010**, 5, 138-142.
- (24) Daaboul, G.; Vedula, R.; Ahn, S.; Lopez, C.; Reddington, A.; Ozkumur, E.; Unlu, M., LED-based Interferometric Reflectance Imaging Sensor for quantitative dynamic monitoring of biomolecular interactions. *Biosensors & Bioelectronics* **2011**, 26, 2221-2227.
- (25) Ozkumur, E.; Yalcin, A.; Cretich, M.; Lopez, C. A.; Bergstein, D. A.; Goldberg, B. B.; Chiari, M.; Unlu, M.S., Quantification of DNA and protein adsorption by optical phase shift. *Biosensors & Bioelectronics* **2009**, 25, 167-172.

- (26) Daaboul, G. G.; Yurt, A.; Zhang, X.; Hwang, G. M.; Goldberg, B. B.; Unlu, M. S., High-Throughput Detection and Sizing of Individual Low-Index Nanoparticles and Viruses for Pathogen Identification. *Nano Letters* **2010**, 10, 4727-4731.
- (27) Armani, D.; Kippenberg, T.; Spillane, S.; Vahala, K., Ultra-high-Q toroid microcavity on a chip. *Nature* **2003**, 421, 925-928.
- (28) Lu, T.; Lee, H.; Chen, T.; Herchak, S.; Kim, J.; Fraser, S.; Flagan, R.; Vahala, K., High sensitivity nanoparticle detection using optical microcavities. *Proceedings of the National Academy of Sciences of the United States of America* **2011**, 108, 5976-5979.
- (29) Yurt, A.; Daaboul, G.; Connor, J.; Goldberg, B.; Unlu, M., Single nanoparticle detectors for biological applications. *Nanoscale* **2012**, 4, 715-726.
- (30) Zeldin, D. C.; Arbes, S. J.; Gergen, P. J.; Elliott, L., Prevalences of positive skin test responses to 10 common allergens in the US population: Results from the Third National Health and Nutrition Examination Survey. *J Allergy Clin Immun* **2005**, 116, 377-383.
- (31) World Health Organization, Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. **2007**.
- (32) Global Industry Analysts. Food Allergy and Intolerance Products: A Global Strategic Business Report. **2012**.
- (33) Chowdhury, F.; Williams, A.; Johnson, P., Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling. *Journal of Immunological Methods* **2009**, 340, 55-64.
- (34) duPont, N.; Wang, K.; Wadhwa, P.; Culhane, J.; Nelson, E., Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: Determinations of a panel of nine

- cytokines in clinical sample culture supernatants. *Journal of Reproductive Immunology* **2005**, 66, 175-191.
- (35) Daaboul, G. G.; Lopez, C. A.; Yurt, A.; Goldberg, B.; Connor, J. H.; Unlu, M. S., Optical Biosensors for Virus Detection and Characterization. *IEEE Journal of Selected Topics in Quantum Electronics* **2011**, 18, 1422-1433.
- (36) Schabacker, D. S.; Stefanovska, I.; Gavin, I.; Pedrak, C.; Chandler, D. P., Protein array staining methods for undefined protein content, manufacturing quality control, and performance validation. *Analytical Biochemistry* **2006**, 359, 84-93.
- (37) Wang, X. J.; Hessner, M. J.; Wu, Y.; Pati, N.; Ghosh, S., Quantitative quality control in microarray experiments and the application in data filtering, normalization and false positive rate prediction. *Bioinformatics* 2003, 19, 1341-1347.
- (38) Monroe, M.; Reddington, A.; Collins, A.; LaBoda, C.; Cretich, M.; Chiari, M.; Little, F.; Unlu, M., Multiplexed Method to Calibrate and Quantitate Fluorescence Signal for Allergen-Specific IgE. *Analytical Chemistry* **2011**, 83, 9485-9491.
- (39) Cretich, M.; Reddington, A.; Monroe, M.; Bagnati, M.; Damin, F.; Sola, L.; Unlu, M.; Chiari, M., Silicon biochips for dual label-free and fluorescence detection: Application to protein microarray development. *Biosensors & Bioelectronics* **2011**, 26, 3938-3943.
- (40) Krishnan, S.; Mani, V.; Wasalathanthri, D.; Kumar, C.; Rusling, J., Attomolar Detection of a Cancer Biomarker Protein in Serum by Surface Plasmon Resonance Using Superparamagnetic Particle Labels. *Angewandte Chemie-International Edition* **2011**, 50, 1175-1178.

- 1
2
3 (41) Sim, H.; Wark, A.; Lee, H., Attomolar detection of protein biomarkers using
4
5 biofunctionalized gold nanorods with surface plasmon resonance. *Analyst* **2010**, 135, 2528-
6
7 2532.
8
9
10 (42) Sheehan, P.; Whitman, L., Detection limits for nanoscale biosensors. *Nano Letters* **2005**,
11
12 5, 803-807.
13
14
15 (43) Gorris, H.; Walt, D., Analytical Chemistry on the Femtoliter Scale. *Angewandte Chemie-*
16
17 *International Edition* **2010**, 49, 3880-3895.
18
19
20 (44) Cretich, M.; Pirri, G.; Damin, F.; Solinas, I.; Chiari, M., A new polymeric coating for
21
22 protein microarrays. *Analytical Biochemistry* **2004**, 332, 67-74.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS


Fig. 1. Detection of β -lactoglobulin in undiluted serum and unprocessed whole blood.

Fig. 1. a) Detection schematic of β -lactoglobulin using anti- β -lactoglobulin functionalized 40nm AuNPs as the detection complex. The mean final diameter of the detection complex after functionalization was measured to be 51nm with dynamic light scattering (DLS). BSA was used as a negative control. b) IRIS images before and after detection complex incubation to detect 5pM of β -lactoglobulin spiked in unprocessed whole blood. c) Histograms of detected particles on the sensor area of anti-B-lactoglobulin probes and the mean, standard deviation (SD), and counts using i) no filtering, ii) anomaly filtering, iii) point spread function (PSF) filtering, and iv) size-discrimination. The size and distribution of the functionalized AuNP diameters agree with the sizes measured by DLS and distribution specs provided by the distributor.

Fig. 2. Effects of PSF filtering on IRIS nanoparticle counting.




Fig. 2. Insets are the log-log plot of each measurement and display the effects of point-spread-function (PSF) filtering on the correlation of the signal to target concentration in undiluted serum. Without PSF filtering, the sensitivity drops from the attomolar to picomolar regime and the dynamic range decreases by 4 logs of magnitude. Standard deviation from the mean also increases without PSF filtering because particulates in the image were falsely detected as gold particles. Finally, correlation of AuNPs per mm² to dilution is reduced from 0.99 to 0.40 without implementing PSF filtering.


Fig. 3. Dilution curves and repeatability

Fig. 3. a) The response determined by the signal minus the limit of detection of either IRIS nanoparticle counting or total biomass measurement. Results demonstrate comparable responses of target detection by nanoparticle counting in serum ($N=8$) and whole blood ($N=4$). Correlation was determined by taking the power-log of the response and target concentration of single nanoparticle data ($R_{\text{serum}}^2 = 0.99$, $R_{\text{whole-blood}}^2 = 0.98$). When the nanoparticle counting measurement reaches its upper limit, total biomass measurement becomes sensitive. Error bars refer to the standard deviation of the mean. b) The response determined by the signal minus the limit of detection (LOD) for 2 serums and 2 whole bloods experiments. The correlation between the mean of each data point (16 total points from 4 experiments) is 0.88. Error bars correspond to the standard deviation between the mean ($N_{\text{serum}} = 8$, $N_{\text{blood}} = 4$).

Fig. 4. Sensor area increase facilitates a lower limit of detection per mm²




Fig. 4 The limit of detection (LOD) per mm² as a function of sensor size for serum and whole blood. At a sensor area of 0.684mm² (8 spots of immobilized probe), the LOD is 62aM for serum and 507aM in whole blood.

Fig. 5. Determination of the upper limit of quantitation




Fig. 5 The upper limit of quantitation (ULQ), defined at where the linear correlation between signal and concentration becomes less than R² = 0.90, was determined to be 100pM for both serum and unprocessed whole blood samples. Y-axis values are the log of the signal (AuNPs per mm²) at each concentration and scaled to see each individual regression line.

Fig. 6. Determination of allergen-specific IgE using IRIS nanoparticle counting in 50 μL characterized patient serum and whole blood.





Fig. 6. Multiplexed assay to detect specific IgE to 8 allergens. Fluorescence measurement was used as a control to validate nanoparticle counting detection ($R^2 = 0.97$ for serum both and whole blood samples). Human sample was characterized with Phadia ImmunoCAP® or skin prick testing (SPT): (+) reflects a positive result. Error bars correspond to the standard deviation from the mean ($n=4$). *Results not determined.



FOR TOC Only
88x44mm (96 x 96 DPI)